1. Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer

   • Masaki Shiota
   • Naohiro Fujimoto
   • Masatoshi Eto

   Original Article 02 March 2020 Pages: 1155 - 1163

   

2. Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach

   • Anat Globerson Levin
   • Natalie Kronik
   • Vladimir Vainstein

   Original Article 04 March 2020 Pages: 1165 - 1175

   

3. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

   • Abdul Rafeh Naqash
   • Biagio Ricciuti
   • Paul R. Walker

   Original Article 05 March 2020 Pages: 1177 - 1187

   

4. Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

   • Abdul Rafeh Naqash
   • Biagio Ricciuti
   • Paul R. Walker

   Correction 28 April 2020 Pages: 1189 - 1189

5. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

   • Tali Voloshin
   • Noa Kaynan
   • Yoram Palti

   Original Article Open access 06 March 2020 Pages: 1191 - 1204

   

6. Adenosine-producing regulatory B cells in head and neck cancer

   • Sandra S. Jeske
   • Matthias Brand
   • Patrick J. Schuler

   Original Article Open access 07 March 2020 Pages: 1205 - 1216

   

7. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo

   • Anja Tatjana Teck
   • Sabrina Urban
   • Sebastian Ochsenreither

   Original Article Open access 10 March 2020 Pages: 1217 - 1227

   

8. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer

   • Ryota Shibaki
   • Shuji Murakami
   • Yuichiro Ohe

   Original Article 10 March 2020 Pages: 1229 - 1236

   

9. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets

   • Diana Tronik-Le Roux
   • Mathilde Sautreuil
   • Edgardo D. Carosella

   Original Article 12 March 2020 Pages: 1237 - 1252

   

10. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes

    • Asmaa M. Zahran
    • Helal F. Hetta
    • Omnia El-Badawy

    Original Article 13 March 2020 Pages: 1253 - 1263

    

11. Tumor immune microenvironment in cancer patients with leukocytosis

    • Kyung Hwan Kim
    • Nam Suk Sim
    • Yong Bae Kim

    Original Article 13 March 2020 Pages: 1265 - 1277

    

12. Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APC^Min/+ mice

    • Louis Szeponik
    • Paulina Akeus
    • Marianne Quiding-Järbrink

    Original Article Open access 17 March 2020 Pages: 1279 - 1292

    

13. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis

    • Guoshu Bi
    • Zhencong Chen
    • Hong Fan

    Original Article 18 March 2020 Pages: 1293 - 1305

    

14. Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target

    • Said Farschtschi
    • Lan Kluwe
    • Andreas Kurtz

    Original Article Open access 19 March 2020 Pages: 1307 - 1313

    

15. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients

    • Maya Dadiani
    • Daniela Necula
    • Adit Ben-Baruch

    Original Article 20 March 2020 Pages: 1315 - 1326

    

16. Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8⁺ T cells in gastric cancer

    • Ruochen Li
    • Heng Zhang
    • Jiejie Xu

    Original Article 21 March 2020 Pages: 1327 - 1336

    

17. In vivo anti-MUC1⁺ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies

    • Edward Pichinuk
    • Michael Chalik
    • Daniel H. Wreschner

    Original Article 26 March 2020 Pages: 1337 - 1352

    

18. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

    • Martin F. Orth
    • Veit Leonhard Buecklein
    • Thomas Knösel

    Original Article 28 March 2020 Pages: 1353 - 1362

    

19. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas

    • Christoph Arolt
    • Moritz Meyer
    • Jens Peter Klussmann

    Original Article Open access 30 March 2020 Pages: 1363 - 1373

    

20. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

    • Qian-Ting Wang
    • Ying Nie
    • You-Wen He

    Clinical Trial Report 20 February 2020 Pages: 1375 - 1387

    

21. Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

    • Alessandra Battaglia
    • Alexia Buzzonetti
    • Christopher Nicodemus

    Correction 26 March 2020 Pages: 1389 - 1389